Company release, 11 August 2022 at 9:30 a.m. (EEST)
Nightingale Health Plc’s (“Nightingale Health”) Board of Directors resolved to change the subscription price of shares in the company’s stock option programs. The change is applicable in all stock option programs that entitle to subscribe for Series B shares.
The new subscription price of each share in the stock option programs is EUR 2.50. Prior to the change the subscription price was EUR 6.75 per share. The subscription price is changed to maintain the purpose of the stock option programs to incentivise the option holders to the economic growth of the company and the development of the company’s market value as well as create a long-term relationship between the company and the option holders.
In all the stock option programs entitling to Series B shares, the right to subscribe for shares is earned mainly based on an increase in Nightingale Health’s market capitalisation. The market capitalisation steps entitling to subscribe for shares in the stock option programs remain unchanged. Subscription right based on market capitalisation is the key term in all these stock option programs, as an increase in the company’s market value is in the best interest of the company’s shareholders.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.